The/O amount/O of/O blood/O surgical/O patients/O can/O donate/O and/O store/O before/O surgery/O can/O be/O increased/O by/O the/O new/O genetically/O engineered/O drug/O ,/O EPO/O ./O
EPO/O ,/O or/O erythropoietin/O ,/O is/O a/O protein/O the/O human/O body/O makes/O to/O stimulate/O the/O growth/O of/O red/O blood/O cells/O ./O
A/O genetically/O engineered/O version/O of/O the/O human/O protein/O developed/O by/O Amgen/B-ORG Corp./I-ORG of/O Thousand/B-GPE Oaks/I-GPE ,/O Calif./B-GPE ,/O recently/O has/O been/O marketed/O by/O the/O Ortho/B-ORG Pharmaceuticals/I-ORG division/O of/O Johnson/B-ORG -AMP-/I-ORG Johnson/I-ORG ./O
A/O competing/O version/O of/O EPO/O is/O being/O developed/O by/O Genetics/B-ORG Institute/I-ORG Inc./I-ORG in/O Cambridge/B-GPE ,/O Mass/B-GPE ./O
The/O drug/O is/O being/O used/O primarily/O to/O treat/O anemias/O ./O
A/O new/O experiment/O ,/O reported/O in/O this/O week/O 's/O New/B-ORG England/I-ORG Journal/I-ORG of/I-ORG Medicine/I-ORG ,/O involved/O giving/O injections/O of/O Amgen/B-ORG 's/O EPO/O to/O 23/O patients/O who/O wanted/O to/O store/O units/O of/O their/O own/O blood/O ./O
The/O patients/O began/O receiving/O EPO/O injections/O about/O a/O month/O before/O their/O scheduled/O surgery/O ./O
They/O then/O began/O donating/O blood/O twice/O a/O week/O ,/O receiving/O an/O EPO/O injection/O each/O time/O ./O
If/O tests/O indicated/O a/O low/O number/O of/O red/O cells/O ,/O blood/O was/O n't/O taken/O ./O
The/O EPO/O -/O treated/O patients/O donated/O an/O average/O of/O 5.4/O units/O of/O blood/O each/O compared/O with/O only/O 4.1/O units/O donated/O by/O a/O similar/O group/O of/O surgical/O patients/O who/O received/O a/O placebo/O injection/O ./O
The/O volume/O of/O red/O cells/O donated/O by/O the/O EPO/O -/O treated/O patients/O was/O 41/O %/O higher/O per/O donor/O ,/O the/O research/O team/O representing/O a/O number/O of/O hospitals/O and/O blood/O banks/O reported/O ./O
